Auris Medical Holding AG

(EARS) Trade

By |

Profile

Auris Medical Holding AG is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects in advanced clinical development Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. Auris Medical is developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL).

Contact Information

Website: www.aurismedical.com
Email: Investors@aurismedical.com
Main Phone: +41 417297194
Address: Bahnhofstrasse 21
City / Town: Zug
Country: CHE
Postal Code: 6300

Issuer Information

Exchange: NSC
CEO: Thomas Meyer
Employees: 24
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 0.44 $ -0.017 (-3.76%)
Last Price 0.44 Change $ -0.017 Change % -3.76 Tick N/A
Bid 0.39 Bid Size 1,500.00 Ask 0.44 Ask Size 2,000.00
Open 0.46 High 0.47 Low 0.42 Prev Close 0.45
Last Trade Volume 982,521 52 Wk Hi 6.60 52 Wk Low 0.23
Market Cap 13 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 29,895,527.00 EPS (TTM) -1.94 PE Ratio N/A Exchange NCM
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 4.5 4.5 4.5 4.5
Low Target Price Estimate 4.5 4.5 4.5 4.5
Mean Target Price Estimate 4.5 4.5 4.5 4.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 08/11/17 08/11/17 08/11/17 08/11/17
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 1
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 0 0 0 1